Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group

被引：1
|
作者：
Rueda, Antonio [1 ]
Calvo, Virginia [2 ]
Casanova, Maria [1 ]
Rodriguez-Abreu, Delvys [3 ]
Aguiar, David [4 ]
Llanos, Marta [5 ]
Alvarez, Ruth [6 ]
Martinez-Banaclocha, Natividad [7 ]
Alfaro, Jesus [8 ]
Quero, Cristina [9 ]
Blasco, Ana [10 ]
de la Cruz Merino, Luis [11 ]
Herrero, Joaquin [12 ]
Garcia-Arroyo, Francisco R. [13 ]
Provencio, Mariano [2 ]
机构：
[1] Hosp Costa Sol, Marbella, Spain
[2] Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain
[3] Hosp Insular, Las Palmas Gran Canaria, Las Palmas, Spain
[4] Hosp Dr Negrin, Las Palmas Gran Canaria, Las Palmas, Spain
[5] Hosp Univ Canarias, Santa Cruz De Tenerife, Spain
[6] Hosp Virgen Salud, Toledo, Spain
[7] Hosp Gen Univ Elche, Alicante, Spain
[8] Oncologikoa, Donostia San Sebastian, Spain
[9] Hosp Univ Gen & Virgen Victoria, Malaga, Spain
[10] Hosp Gen Univ, Valencia, Spain
[11] Hosp Virgen Macarena, Seville, Spain
[12] Hosp Gen Univ Alicante, Alicante, Spain
[13] Complexo Hosp Univ Pontevedra, Pontevedra, Spain
来源：
LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 06期
关键词：
NON-HODGKIN-LYMPHOMA; INDOLENT B-CELL; PLUS RITUXIMAB; MANTLE-CELL; 1ST-LINE TREATMENT; OPEN-LABEL; RELAPSED INDOLENT; MULTICENTER; OBINUTUZUMAB; THERAPY;
D O I：
10.1080/10428194.2018.1542147
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1576 / 1579
页数：4
相关论文
共 50 条
  • [31] Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design
    Kumar, Anita
    Casulo, Carla
    Joffe, Erel
    Moskowitz, Craig
    Gerecitano, John
    Moskowitz, Alison
    Younes, Anas
    Drullinsky, Pamela
    Drill, Esther
    Choma, Morgan
    Grieve, Clare
    Joseph, Ashlee
    Laraque, Leana
    Schick, Dylan
    Zelenetz, Andrew
    Hamlin, Paul
    LEUKEMIA & LYMPHOMA, 2022, 63 (12) : 2889 - 2896
  • [32] Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group
    Gogas, H
    Bafaloukos, D
    Aravantinos, G
    Fountzilas, G
    Tsoutsos, D
    Panagiotou, P
    Frangia, K
    Kalofonos, HP
    Briasoulis, E
    Castana, O
    Polyzos, A
    Pectasides, D
    Ioannovich, J
    CANCER INVESTIGATION, 2004, 22 (06) : 832 - 839
  • [33] Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)
    Zettl, Florian
    Braulke, Friederike
    Ziepert, Marita
    Viardot, Andreas
    Kahl, Christoph
    Prange-Krex, Gabriele
    Korfel, Agnieszka
    Dreyling, Martin H.
    Illmer, Thomas
    Birkmann, Josef
    Wedding, Ulrich
    Reichert, Dietmar
    de Wit, Maike
    Hartmann, Frank
    Hurtz, Hans-Juergen
    Schmitz, Norbert
    Witzens-Harig, Mathias
    Klapper, Wolfram
    Rosenwald, Andreas
    Poeschel, Viola
    Loeffler, Markus
    Wulf, Gerald
    Altmann, Bettina
    Truemper, Lorenz
    BLOOD, 2019, 134
  • [34] Results of a phase II study employing a combination of fludarabine, cyclophosphamide and rituximab (FCR) as primary therapy for patients with advanced follicular lymphoma (FL): The Israel Cooperative Lymphoma Group.
    Cohen, A
    Polliack, A
    Ben-Bassat, I
    Avigdor, A
    Bennett, M
    Berkowicz, M
    Attias, D
    Dann, E
    Hatskelzon, L
    Levi, I
    Libster, D
    Rahmani, R
    Raanani, P
    Rowe, JM
    Shtalrid, M
    Yerushalmi, R
    Yeshurun, M
    BLOOD, 2002, 100 (11) : 360A - 360A
  • [35] Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
    Davies, Andrew
    Merli, Francesco
    Mihaljevic, Biljana
    Mercadal, Santiago
    Siritanaratkul, Noppadol
    Solal-Celigny, Philippe
    Boehnke, Axel
    Berge, Claude
    Genevray, Magali
    Zharkov, Artem
    Dixon, Mark
    Brewster, Michael
    Barrett, Martin
    MacDonald, David
    LANCET HAEMATOLOGY, 2017, 4 (06): : E272 - E282
  • [36] A Phase I/II trial of fruquintinib in combination with paclitaxel for second-line treatment in patients with advanced gastric cancer.
    Xu, Rui-hua
    Zhang, Dongsheng
    Shen, Lin
    Li, Jin
    Huang, Jing
    Gong, Jifang
    Guo, Weijian
    Zhang, Yang
    Fan, Songhua
    Li, Ke
    Hua, Ye
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [37] Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trial
    Phillips, Tycel
    Wang, Michael
    Robak, Tadeusz
    Gallinson, David
    Stevens, Don
    Patel, Krish
    Ramadan, Safaa
    Wun, Chuan-Chuan
    Jurczak, Wojciech
    Smith, Stephen D.
    HAEMATOLOGICA, 2025, 110 (03) : 715 - 724
  • [38] Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months.
    Buske, Christian
    Hoster, Eva
    Dreyling, Martin
    Forstpointner, Roswitha
    Kneba, Michael
    Schmitz, Norbert
    Schmits, Rudolf
    Metzner, Bernd
    Reiser, Marcel
    Lengfelder, Eva
    Woermann, Bernhard J.
    Harder, Harriet
    Hegewisch-Becker, Susanna
    Berdel, Wolfgang E.
    Hess, Georg
    Eimermacher, Hartmut
    Aldaoud, Ali
    Planker, Manfred
    Unterhalt, Michael
    Hiddemann, Wolfgang
    BLOOD, 2008, 112 (11) : 901 - 901
  • [39] Phase I/II trial shows promising efficacy of nadunolimab in combination with platinum doublet as second-line therapy in patients with NSCLC
    Paulus, A.
    Zemaitis, M.
    Cicenas, S.
    Zvirbule, Z.
    Rydberg-Millrud, C.
    Magnusson, S.
    Losic, N.
    Tersago, D.
    Paz-Ares, L. G.
    ANNALS OF ONCOLOGY, 2024, 35 : S853 - S853
  • [40] Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular non-Hodgkin's lymphoma in Sweden
    Kasteng, F.
    Erlanson, M.
    Hagberg, H.
    Kimby, E.
    Relander, T.
    Lunckvist, J.
    VALUE IN HEALTH, 2007, 10 (06) : A331 - A331
12345